1. Short title This Act may be cited as the Accelerating Access to Critical Therapies for ALS Act . 2. Grants for rapid development of therapies for ALS and other rapidly progressing neurodegenerative diseases (a) In general The Secretary of Health and Human Services shall award grants to eligible entities for the provision of investigational drugs through an expanded access program pursuant to section 561 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 360bbb ) for individuals for the prevention, diagnosis, mitigation, treatment, or cure of amyotrophic lateral sclerosis or another rapidly progressing neurodegenerative disease. (b) Vested authority For purposes of development of an investigational drug pursuant to subsection (a), the Secretary may vest authority in the participating clinical trial site or sites to make the determination under subsection (b)(2), (c)(6), or (c)(7), as applicable, of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 360bbb ). (c) Timing Not later than 60 days after the date of submission of an application for a grant under this section— (1) the Secretary, acting through the Director of the National Institutes of Health, shall determine whether to award the grant